GlobeNewswire: Cyclacel Contains the last 10 of 385 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:10:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848964/0/en/Cyclacel-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update2024-03-19T20:05:00Z<![CDATA[– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 –]]>https://www.globenewswire.com/news-release/2024/03/13/2845845/0/en/Cyclacel-Pharmaceuticals-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results2024-03-13T20:05:00Z<![CDATA[BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day.]]>https://www.globenewswire.com/news-release/2024/03/07/2842334/0/en/Cyclacel-Pharmaceuticals-Announces-Preclinical-Proof-of-Concept-Data-for-Fadraciclib-to-be-Presented-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 20242024-03-07T14:15:00Z<![CDATA[Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma]]>https://www.globenewswire.com/news-release/2024/03/06/2841513/0/en/Cyclacel-Pharmaceuticals-Announces-Receipt-of-2-9-Million-R-D-Tax-Credit.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit2024-03-06T14:15:00Z<![CDATA[BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures.]]>https://www.globenewswire.com/news-release/2024/02/20/2831952/0/en/Cyclacel-Pharmaceuticals-to-Participate-in-2024-BIO-CEO-Investor-Conference.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference2024-02-20T14:15:00Z<![CDATA[BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.]]>https://www.globenewswire.com/news-release/2024/01/30/2820102/0/en/Cyclacel-Pharmaceuticals-Announces-the-Appointment-of-Brian-Schwartz-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer2024-01-30T14:15:00Z<![CDATA[BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company.]]>https://www.globenewswire.com/news-release/2024/01/08/2805562/0/en/Cyclacel-Pharmaceuticals-Regains-Compliance-With-Nasdaq-Minimum-Bid-Price-Requirement.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement2024-01-08T14:15:00Z<![CDATA[BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.]]>https://www.globenewswire.com/news-release/2024/01/02/2802719/0/en/Cyclacel-Pharmaceuticals-to-Present-at-Biotech-Showcase-2024.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals to Present at Biotech Showcase 20242024-01-02T14:15:00Z<![CDATA[BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.]]>https://www.globenewswire.com/news-release/2023/12/22/2800620/0/en/Cyclacel-Pharmaceuticals-Announces-Registered-Direct-and-Private-Placement-Offering-Priced-At-The-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules2023-12-22T14:15:00Z<![CDATA[BERKELEY HEIGHTS, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company will also issue unregistered warrants to purchase up to 388,200 shares of common stock with an exercise price of $3.19 per share which will be immediately exercisable for a period of seven years following issuance. The closing of the offering is expected to occur on or about December 26, 2023, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/12/18/2797893/0/en/Cyclacel-Pharmaceuticals-Reports-Fadraciclib-Phase-1-Data-Suggesting-Efficacy-Against-Tumors-With-CDKN2A-CDKN2B-and-MTAP-Deletions.html?f=22&fvtc=4&fvtv=8289Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions2023-12-18T14:00:00Z<![CDATA[- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels -]]>